Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...

Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...

These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population—add to previously published evidence of its strong ...

Masimo’s NeoPODS study in critically ill newborns found its SET pulse oximetry technology delivered consistent accuracy across all skin tones, with less than 1% bias. The findings address longstanding ...

Joe Kiani, Founder and CEO of Masimo, said, “Until now, consumers and even healthcare providers had no way of knowing what pulse oximeter they could trust to use at home. On the internet and even in ...

At the heart of the expanded partnership is a joint effort to integrate Masimo’s advanced monitoring technologies – including SET® pulse oximetry, Radius PPG, and a range of sensor technology – into ...

About a week after the FDA convened its latest meeting to discuss strategies for reducing racial biases in widely available pulse oximetry technology, Masimo has released new study data suggesting ...

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient ...

Masimo (Nasdaq:MASI) today announced new study findings supporting the use of its SET pulse oximetry in critically ill neonates.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today FDA clearance of MightySat ® Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available ...